NCT00186966View on ClinicalTrials.gov

Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia

PHASE3CompletedINTERVENTIONAL
Enrollment

394

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

April 30, 2009

Study Completion Date

September 30, 2010

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome)

See Detailed Description section for details of treatment interventions.

DRUG

Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan

See Detailed Description section for details of treatment interventions.

PROCEDURE

Hematopoietic stem cell transplant

See Detailed Description section for details of treatment interventions.

RADIATION

Total body irradiation

See Detailed Description section for details of treatment interventions.

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
collaborator

International BFM Study Group

NETWORK

collaborator

St. Jude Children's Research Hospital

OTHER

lead

Dutch Childhood Oncology Group

OTHER

NCT00186966 - Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter